Literature DB >> 25363147

Pediatric super-refractory status epilepticus treated with allopregnanolone.

Eileen Broomall1, JoAnne E Natale, Michele Grimason, Joshua Goldstein, Craig M Smith, Celia Chang, Stephen Kanes, Michael A Rogawski, Mark S Wainwright.   

Abstract

Super-refractory status epilepticus is a life-threatening condition. Resistance to benzodiazepine and barbiturate treatment for this disorder is thought to be due to internalization of synaptic γ-aminobutyric acid (GABA)A receptors, and withdrawal of benzodiazepines and barbiturates during treatment often triggers seizure recurrence. The neurosteroid allopregnanolone acts as a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors. Here we describe the use of allopregnanolone in 2 pediatric patients with super-refractory status epilepticus. This treatment allowed the general anesthetic infusions to be weaned with resolution of status epilepticus. This is the first report of allopregnanolone use to treat status epilepticus in children.
© 2014 American Neurological Association.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25363147      PMCID： PMC4534165          DOI： 10.1002/ana.24295

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  13 in total

Review 1.  The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol.

Authors:  Simon Shorvon; Monica Ferlisi
Journal:  Brain       Date:  2011-09-13       Impact factor: 13.501

2.  Pharmacokinetic and behavioral effects of allopregnanolone in healthy women.

Authors:  Erika Timby; Matts Balgård; Sigrid Nyberg; Olav Spigset; Agneta Andersson; Joanna Porankiewicz-Asplund; Robert H Purdy; Di Zhu; Torbjörn Bäckström; Inger Sundström Poromaa
Journal:  Psychopharmacology (Berl)       Date:  2005-09-21       Impact factor: 4.530

3.  Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial.

Authors:  J F Kerrigan; W D Shields; T Y Nelson; D L Bluestone; W E Dodson; B F Bourgeois; J M Pellock; L D Morton; E P Monaghan
Journal:  Epilepsy Res       Date:  2000-12       Impact factor: 3.045

4.  Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature.

Authors:  Gary Ginsberg; Dale Hattis; Babasaheb Sonawane; Abel Russ; Prerna Banati; Mary Kozlak; Susan Smolenski; Rob Goble
Journal:  Toxicol Sci       Date:  2002-04       Impact factor: 4.849

5.  Treatment of status epilepticus: an international survey of experts.

Authors:  James J Riviello; Jan Claassen; Suzette M LaRoche; Michael R Sperling; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Lori Shutter; David M Treiman; Paul M Vespa; Rodney Bell; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

Review 6.  Refractory status epilepticus: new insights in presentation, treatment, and outcome.

Authors:  Sara Hocker; Eelco F M Wijdicks; Alejandro A Rabinstein
Journal:  Neurol Res       Date:  2012-12-13       Impact factor: 2.448

Review 7.  Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).

Authors:  Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Journal:  Epilepsy Res       Date:  2012-12-04       Impact factor: 3.045

8.  Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation.

Authors:  T G Kokate; B E Svensson; M A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

Review 9.  The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy.

Authors:  Monica Ferlisi; Simon Shorvon
Journal:  Brain       Date:  2012-05-09       Impact factor: 13.501

10.  Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease.

Authors:  Stephen G Brickley; Istvan Mody
Journal:  Neuron       Date:  2012-01-12       Impact factor: 17.173
View more
  27 in total

1.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Treatment of Convulsive Status Epilepticus.

Authors:  Eric H Grover; Yara Nazzal; Lawrence J Hirsch
Journal:  Curr Treat Options Neurol       Date:  2016-03       Impact factor: 3.598

3.  Neurosteroid Deficiency Associated With Epilepsy.

Authors:  Jamie Maguire
Journal:  Epilepsy Curr       Date:  2016 Mar-Apr       Impact factor: 7.500

Review 4.  Treatment of Refractory and Super-refractory Status Epilepticus.

Authors:  Samhitha Rai; Frank W Drislane
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 5.  Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research.

Authors:  P Porcu; A M Barron; C A Frye; A A Walf; S-Y Yang; X-Y He; A L Morrow; G C Panzica; R C Melcangi
Journal:  J Neuroendocrinol       Date:  2016-02       Impact factor: 3.627

Review 6.  Pathophysiology of convulsive status epilepticus.

Authors:  Iván Sánchez Fernández; Howard P Goodkin; Rod C Scott
Journal:  Seizure       Date:  2018-08-06       Impact factor: 3.184

Review 7.  Defects at the crossroads of GABAergic signaling in generalized genetic epilepsies.

Authors:  Jing-Qiong Kang
Journal:  Epilepsy Res       Date:  2017-08-26       Impact factor: 3.045

Review 8.  Status Epilepticus.

Authors:  Syndi Seinfeld; Howard P Goodkin; Shlomo Shinnar
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

Review 9.  A Rationale for Allopregnanolone Treatment of Alcohol Use Disorders: Basic and Clinical Studies.

Authors:  A Leslie Morrow; Giorgia Boero; Patrizia Porcu
Journal:  Alcohol Clin Exp Res       Date:  2019-12-17       Impact factor: 3.455

Review 10.  Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy.

Authors:  Sima I Patel; Angela K Birnbaum; James C Cloyd; Ilo E Leppik
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.